HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro's syndrome: A case report.

Abstract
Shapiro's syndrome (SS) is a rare neurological disorder characterized by spontaneous periodic hypothermia and hyperhidrosis without identifiable systemic causes or brain injuries. We present the case of F. a young patient, without agenesis of the corpus callosum and with episodes of recurrent hypothermia, who was successfully immunized against SARS-CoV-2 via vaccination. F. was born on 2012 and started suffering from episodes of hypothermia at the age of three, with body temperature reaching as low as 32.8°C Hypothermia episodes were initially associated with ibuprofen intake, but were later defined as symptoms of SS. No SARS-CoV-2 infections had been reported before vaccination. The subject received the first dose of pediatric formulation anti-SARS-CoV-2 Comirnaty vaccine on 11 January 2022 and the second dose on 5 February 2022. A one-week follow-up for adverse events was performed via telephone contact after both administrations. Further contact occurred one month after immunization. Anti-SARS-CoV-2 IgG titers were evaluated fifteen days after administration of the second dose. Following vaccination, slight fluctuations in body temperature and local adverse events were noted. These adverse events were not worrying; the vaccine's safety profile is therefore confirmed. The child also developed an excellent antibody titer (>28x103 AU/ml), thus suggesting a good immune response.
AuthorsLorenza Moscara, Silvio Tafuri, Delio Gagliardi, Pasquale Stefanizzi
JournalHuman vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 18 Issue 6 Pg. 2094148 (Nov 30 2022) ISSN: 2164-554X [Electronic] United States
PMID35763557 (Publication Type: Case Reports, Journal Article)
Chemical References
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • RNA, Messenger
Topics
  • Humans
  • Child
  • BNT162 Vaccine
  • COVID-19 Vaccines (adverse effects)
  • RNA, Messenger
  • SARS-CoV-2
  • COVID-19 (prevention & control)
  • Immunogenicity, Vaccine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: